Cancer immunotherapy: the art of targeting the tumor immune microenvironment Jesse Lopes da SilvaAlexssandra Lima S. Dos SantosAndreia Cristina de Melo Review Article 25 June 2019 Pages: 227 - 240
The role of apoptosis defects in malignant mesothelioma pathogenesis with an impact on prognosis and treatment Vasiliki GalaniAnna VarouktsiYotanna Dalavanga Review Article 22 May 2019 Pages: 241 - 253
Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations Carmen F. NobreMatthew J. NewmanPauline Newman Review Article Open access 27 May 2019 Pages: 255 - 263
Priming with GM-CSF instead of G-CSF enhances CAG-induced apoptosis of acute monocytic leukemia cells in vitro Meiqing LeiLimin LiuDepei Wu Original Article 21 May 2019 Pages: 265 - 273
Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients Kazutaka HosoyaDaichi FujimotoKeisuke Tomii Original Article 14 June 2019 Pages: 275 - 280
Neoadjuvant chemotherapy in patients with advanced endometrial cancer Olivia R. KhouriMelissa K. FreyBhavana Pothuri Original Article 12 April 2019 Pages: 281 - 285
SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4 Deysi Viviana Tenazoa WongHelder Veras Ribeiro-FilhoRoberto César Pereira Lima-Júnior Original Article 22 April 2019 Pages: 287 - 298
Postoperative chemotherapy as adjuvant treatment for endometrioid adenocarcinoma: early stage vs late stage Mengmeng LuJiaojiao ZhengShaogui Wan Original Article 29 April 2019 Pages: 299 - 305
Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer Takeshi SuzukiEiji ShinozakiKensei Yamaguchi Original Article 07 May 2019 Pages: 307 - 313
A panel of serum exosomal microRNAs as predictive markers for chemoresistance in advanced colorectal cancer Guoying JinYuhang LiuZhaohui Huang Original Article 14 May 2019 Pages: 315 - 325
Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody–drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII Mark RosenthalRichard CurryTimothy Cloughesy Original Article 01 June 2019 Pages: 327 - 336
Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers Hironobu MinamiYutaka FujiwaraAtsuko Moriya Original Article 12 June 2019 Pages: 337 - 343
Oxaliplatin induces prostaglandin E2 release in vascular endothelial cells Satoru MatsunumaSatoko HandaYasuhisa Kato Original Article 26 June 2019 Pages: 345 - 350
A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer Yasuhiro KatoYusuke OkumaTatsuru Okamura Original Article Open access 16 April 2019 Pages: 351 - 358
Exposure time versus cytotoxicity for anticancer agents David M. EvansJianwen FangBeverly A. Teicher Original Article 17 May 2019 Pages: 359 - 371
Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis Aurélie PétainDafang ZhongPierre Ferré Original Article Open access 27 May 2019 Pages: 373 - 382
The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors Shodeinde A. CokerHerbert I. HurwitzLionel D. Lewis Original Article 11 June 2019 Pages: 383 - 392
Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors Toshihiko DoiYutaka FujiwaraShunji Takahashi Original Article Open access 21 June 2019 Pages: 393 - 404
Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors Gyuri KimMyungeun YooByoung Chul Cho Original Article 27 June 2019 Pages: 405 - 414
MSI2-TGF-β/TGF-β R1/SMAD3 positive feedback regulation in glioblastoma Xingjun JiangJun TanCaiping Ren Original Article 27 June 2019 Pages: 415 - 425
MicroRNA-552 deficiency mediates 5-fluorouracil resistance by targeting SMAD2 signaling in DNA-mismatch-repair-deficient colorectal cancer Ping ZhaoYu-guang MaHai-tao Guan Original Article 13 May 2019 Pages: 427 - 439
An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine I. KümlerR. L. EefsenD. L. Nielsen Short Communication 04 April 2019 Pages: 441 - 446
CNS penetration of the CDK4/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors Yogesh T. PatelAbigail DavisClinton F. Stewart Short Communication 11 May 2019 Pages: 447 - 452